- Despite the introduction of new and improved drugs for multiple myeloma, some groups of patients remain resistant to therapy.
- Our R&D activity aims to develop innovative drugs to help patients resistant to existing treatment.
- Efficacy has been confirmed in cell-based in vitro assays.
- Planning is underway for a GLP safety trial.
- Planning is underway for compound manufacture to GMP standards.